Skip to main content

View full-text article in PMC

. 2001 Apr 10;2:2. doi: 10.1186/1471-2172-2-2

Table 1.

Lymphocyte subpopulations from control lymph nodes, tonsils and reactive lymph nodes to head and neck carcinoma

	*Control*	*lymph*				*Reactive lymph nodes to lead*
	*nodes*		Tonsils			*and neck carcinoma*
*ANTIGEN*	N	Mean ±	N	*Mean* ±	*P^a) (Tonsil*	N		*P^a)(reactive*
		SD		SD	*Vs control)*		Mean ± SD	*Vs control)*

CD7	27	68 ± 10	9	48 ± 11	0.0002	62	62 ± 11	0.01
CD19	26	24 ± 10	9	40 ± 15	0.004	63	30 ± 11	0.05
CD4	26	58 ± 10	9	42 ± 10	0.0005	65	56 ± 12	NS
CD8	27	12 ± 5	9	8 ± 1	0.002	65	9 ± 4	0.03
CD45RA	28	63 ± 9	9	54 ± 17	NS	64	58 ± 12	NS
CD45RO	28	29 ± 8	9	31 ± 9	NS	63	33 ± 10	NS
CD7/CD45RA	25	37 ± 14	9	16 ± 4	0.0004	60	29 ± 10	0.004
CD7/CD45RO	26	24 ± 8	9	27 ± 9	NS	60	28 ± 8	NS
CD69	8	14 ± 12	9	29 ± 10	0.02	14	23 ± 10	NS
CD3/CD69	7	12 ± 11	9	21 ± 10	NS	14	19 ± 8	NS

^a) P < 0.05 by Kruskal-Wallis test considered significant. NS means no significant.